Filters
Results 1 - 1 of 1
Results 1 - 1 of 1.
Search took: 0.028 seconds
AbstractAbstract
[en] In patients treated for malignant testicular tumours without clinical and/or radiological signs of tumour, the following serum hormone levels were found. In 15% of the patients there was a slight to moderate rise in luteinising hormone (LH) levels (up to 6μg/1) due to increased pituitary gonadotrophin production; this was particularly evident soon after radiotherapy/chemotherapy. In 50% of the patients there was a slight to marked increase to follicle stimulating hormone (FSH) levels (up to 11μg/1), especially after radiotherapy/chemotherapy. Serum testosterone levels were in the low range (up to 20 nmol/1) in the majority of the hemicastrated patients regardless of previous treatment. A slight to moderate rise in serum oestradiol-17β and serum prolactin levels was noted. During combination chemotherapy with vincristine, Adriamycin D, cyclophosphamide, actinomycin D and medroxyprogesterone acetate the serum testosterone levels were extremely low (below 6 nmol/1) with LH and FSH levels within the normal range. The decrease in testosterone levels was reversible after completion of the combination chemotherapy. (author)
Primary Subject
Record Type
Journal Article
Journal
British Journal of Urology; ISSN 0007-1331; ; v. 52(2); p. 151-157
Country of publication
ALKALOIDS, ALKYLATING AGENTS, ANDROGENS, ANDROSTANES, ANTIBIOTICS, ANTIMITOTIC DRUGS, BODY, CARBOHYDRATES, DISEASES, DRUGS, ESTRANES, ESTROGENS, GLYCOPROTEINS, GONADOTROPINS, GONADS, HORMONES, HYDROXY COMPOUNDS, KETONES, MALE GENITALS, MEDICINE, ORGANIC COMPOUNDS, ORGANS, PEPTIDE HORMONES, PITUITARY HORMONES, PREGNANES, PROTEINS, SACCHARIDES, STEROID HORMONES, STEROIDS, SURGERY, THERAPY, UROGENITAL SYSTEM DISEASES
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue